Trial Profile
Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Thrombomodulin alfa (Primary) ; Methylprednisolone; Prednisolone
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Asahi Kasei
- 09 Jan 2020 Primary endpoint has been met. (Survival rate on Day 90)
- 09 Jan 2020 Results determining the efficacy and safety of thrombomodulin alfa compared with placebo in acute exacerbation of idiopathic pulmonary fibrosispublished in the American Journal of Respiratory and Critical Care Medicine
- 17 Jan 2019 Status changed from active, no longer recruiting to completed.